How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

906 results for

Hair Disorders in Black Patients

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Hair Disorders in Black Patients

Hair Disorders in Black Patients Hair Disorders in Black Patients Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hair Disorders (...) in Black Patients Hair Disorders in Black Patients Aka: Hair Disorders in Black Patients , Hair Conditions in African American Persons , Hair Care Practices in Persons of African Descent From Related Chapters II. Physiology Characteristics of hair in black patients High degree of curl Fragile Dry with less sebum production care practices have developed to manage the unique hair characteristics and may result in adverse effects Hair ing is reduced to every 1-2 weeks to prevent excessive drying May

2018 FP Notebook

2. Pharmacological Treatment of Patients with Alcohol Use Disorder

Pharmacological Treatment of Patients with Alcohol Use Disorder THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE Pharmacological Treatment of Patients With Alcohol Use Disorder THE AMERICAN PSYCHIATRIC ASSOCIATION PRACTICE GUIDELINE FOR THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH ALCOHOL USE DISORDER WWW.APPI.ORG A lcohol use disorder (AUD) is a major public health problem in the United States. The estimated 12-month and lifetime prevalence values for AUD are 13.9% and 29.1 (...) , and treatment is associated with reductions in the risk of relapse and AUD- associated mortality. The American Psychiatric Association Practice Guideline for the Pharmacological Treatment of Patients With Alcohol Use Disorder seeks to reduce these substantial psychosocial and public health consequences of AUD for millions of affected individu- als. The guideline focuses specifically on evidence-based pharmacological treatments for AUD in outpatient settings and includes additional information on assessment

2017 American Psychiatric Association

3. Hair Disorders in Black Patients

Hair Disorders in Black Patients Hair Disorders in Black Patients Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 Hair Disorders (...) in Black Patients Hair Disorders in Black Patients Aka: Hair Disorders in Black Patients , Hair Conditions in African American Persons , Hair Care Practices in Persons of African Descent From Related Chapters II. Physiology Characteristics of hair in black patients High degree of curl Fragile Dry with less sebum production care practices have developed to manage the unique hair characteristics and may result in adverse effects Hair ing is reduced to every 1-2 weeks to prevent excessive drying May

2015 FP Notebook

4. Inpatient care for children and adolescents with mental disorders

different stakeholder groups (including treating clinicians, parents, teachers and young persons) over different time periods that impact on comparability of findings and the definition of effectiveness. Finally, the evidence is mostly based on small sample sizes, which limit the ability to assess the relative effectiveness of treatment models for different patient or service delivery characteristics. INPATIENT CARE FOR CHILDREN AND ADOLESCENTS WITH MODERATE-TO-SEVERE MENTAL DISORDERS | SAX INSTITUTE 7 (...) is needed regarding the impact of different treatment variables on patient outcomes and to determine if this differs by specific sub-populations. That includes development and evaluation of a range of flexible and innovative integrated models of care across inpatient and community- based settings. 10 INPATIENT CARE FOR CHILDREN AND ADOLESCENTS WITH MODERATE-TO-SEVERE MENTAL DISORDERS | SAX INSTITUTE 2 Background A recent Australian mental health survey of children and adolescents aged between 4 and 17

2018 Sax Institute Evidence Check

5. Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic

is warranted. Screening tests should be easily administered, acceptable to patients, and economical. In this report, we refer to screening as a universally administered questionnaire designed to ascertain who is at high risk for having a substance use disorder in pregnancy. Biologic testing of urine, blood, or hair is discussed as a test and not as a screening technique. A biologic test may be useful only in selected situations. Universal biologic testing to screen pregnant women is not recommended. When (...) for therapeutic maintenance should be made with the use of an individualized, patient-centered approach that is based on the disease model of substance use disorder. • Although the US Food and Drug Administration (FDA) has approved naltrexone for the treatment of OUD, data are insufficient to support the initiation of naltrexone therapy during pregnancy. Naltrexone may be continued for those patients who already are taking this medication and who become pregnant after a careful assessment and communication

2019 Society for Maternal-Fetal Medicine

6. Clinical spectrum of woolly hair: indications for cerebral involvement (PubMed)

Clinical spectrum of woolly hair: indications for cerebral involvement Woolly Hair is an uncommon congenital anomaly of the scalp hair presenting with strongly coiled hair involving a localized area of the scalp or covering the entire side and occurring in non-black people. Isolated or localized wooly hair is usually benign and is not related to other disorders and/or complications. On the contrary, the generalized type may be related to disorders and syndromes affecting heart, cutis, liver (...) and gastrointestinal organs. Among the syndromes presenting with wooly hair, the most known are the Naxos syndrome, the Carvajal-Huerta syndrome, the wooly hair/hypotrichosis, the ectodermal dysplasia-skin fragility, the tricho-hepato-enteric syndrome.To our knowledge, no cases of wooly hair syndromes has been associated to neurologic involvement. Among the clinical notes of patients admitted in the Pediatric Units of the Catania University, we have selected four individuals presenting wooly hair, who showed

Full Text available with Trip Pro

2017 Italian journal of pediatrics

7. Efficacy and Safety of a Nutraceutical Supplement With Standardized Botanicals in Women With Thinning Hair

target area (1 cm by 1 cm) of each subject at each visit as specified under the Schedule of Procedures. The digital macrophotographs will show the five black colored markings on the scalp that define the target area. Digital macrophotographs will be performed using a Canon Power Shot G16 with 3GEN Dermlite FOTO Pro system.The macrophotographs are then read by the investigator to determine the terminal hair count. Number of vellus hairs in the target area of the scalp. [ Time Frame: 180 days (...) ] The second primary efficacy parameter from the digital macrophotographs will be the number of vellus hairs in the target area of the scalp. Vellus hair is defined as fine, short hairs found on the scalp with maximum cross-sectional diameter of 40 micrometers. Digital macrophotographs will be taken of the selected target area (1 cm by 1 cm) of each subject at each visit as specified under the Schedule of Procedures. The digital macrophotographs will show the five black colored markings on the scalp

2017 Clinical Trials

8. Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks

Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks Clinical and Molecular Characteristics of Primary Aldosteronism in Blacks - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Clinical (...) and Molecular Characteristics of Primary Aldosteronism in Blacks The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03374215 Recruitment Status : Recruiting First Posted : December 15, 2017 Last Update Posted : February 11, 2019 See

2017 Clinical Trials

9. Clinical Evaluation of Hair Removal and Permanent Hair Reduction for Skin Types VI Using Intense Pulsed Light

Intervention/treatment Experimental: Treatment Group Hair removal treatment using Venus Versa IPL energy Device: Venus Versa The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures. The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters (...) members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 21 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: Yes Criteria Inclusion Criteria: Able to read, understand and provide written Informed Consent; Subject has black or dark brown terminal hairs

2015 Clinical Trials

10. Evidence-based guidelines for treating bipolar disorder

and presented, like previous Clinical Practice Guidelines, as recommendations to aid clinical decision making for practitioners: it may also serve as a source of information for patients and carers, and assist audit. The recommendations are presented together with a more detailed review of the corresponding evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up (...) likely), and upgrades other findings (e.g. from observational studies in large samples with strong quasi-experi- mental designs). Where evidence is sparse, it has been necessary to extrapolate from relevant evidence where it is available. Weaker levels of recommendation may cover key areas of prac- tice. Recommendations will be starred as in Table 2. Scope and target of the guidelines The content of the guidelines is relevant for all doctors treating patients with bipolar disorder. We hope

2016 British Association for Psychopharmacology

11. Evidence-based Guidelines for Treating Bipolar Disorder

and presented, like previous Clinical Practice Guidelines, as recommendations to aid clinical decision making for practitioners: it may also serve as a source of information for patients and carers, and assist audit. The recommendations are presented together with a more detailed review of the corresponding evidence. A consensus meeting, involving experts in bipolar disorder and its treatment, reviewed key areas and considered the strength of evidence and clinical implications. The guidelines were drawn up (...) likely), and upgrades other findings (e.g. from observational studies in large samples with strong quasi-experi- mental designs). Where evidence is sparse, it has been necessary to extrapolate from relevant evidence where it is available. Weaker levels of recommendation may cover key areas of prac- tice. Recommendations will be starred as in Table 2. Scope and target of the guidelines The content of the guidelines is relevant for all doctors treating patients with bipolar disorder. We hope

2016 British Association for Psychopharmacology

12. 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension

24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record (...) Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. 24 Week Efficacy and Safety Study of Empagliflozin (BI 10773) in Hypertensive Black/African American Patients With Type 2 Diabetes Mellitus and Hypertension The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal

2014 Clinical Trials

13. Global Vascular Guidelines for patients with chronic limb-threatening ischemia

Global Vascular Guidelines for patients with chronic limb-threatening ischemia Global vascular guidelines on the management of chronic limb-threatening ischemia - Journal of Vascular Surgery Email/Username: Password: Remember me Search JVS Journals Search Terms Search within Search Access provided by Volume 69, Issue 6, Supplement, Pages 3S–125S.e40 Global vascular guidelines on the management of chronic limb-threatening ischemia x Michael S. Conte Affiliations Division of Vascular (...) –938 ---- | ---- Fig 3.1 Flow diagram for the investigation of patients presenting with suspected chronic limb-threatening ischemia (CLTI). ABI, Ankle-brachial index; PAD, peripheral artery disease; TBI, toe-brachial index; WIfI, Wound, Ischemia, and foot Infection. ---- | ---- Fig 3.2 Suggested algorithm for anatomic imaging in patients with chronic limb-threatening ischemia ( CLTI ) who are candidates for revascularization. In some cases, it may be appropriate to proceed directly to angiographic

Full Text available with Trip Pro

2019 Society for Vascular Surgery

14. Attention-Deficit Hyperactivity Disorder

or treatment must be made by the physician in light of the circumstances presented by the patient. Attention-Deficit Hyperactivity Disorder Patient population. Children and young adults age 3 to 30 years. Considerations for preschool children (3-5) and adults (18-30) are discussed (see Special Populations). Objectives. 1. Recognize and treat ADHD early in the primary care setting. 2. Identify appropriate treatment options and drug side effects. 3. Identify common co-morbidities and indications for referral (...) . 4. Identify appropriate support resources for patients and their families. Key Points Epidemiology Common. ADHD is the most common behavioral disorder in school-age children – a U.S. community prevalence of 6-8% that is more common in boys [C]. In at least 30% of diagnosed children ADHD continues into adulthood, with 3-4% of adults meeting criteria for ADHD [C]. Primary care provider. Most children with ADHD receive care through primary care physicians. Diagnosis Types. Diagnosis is based

2013 University of Michigan Health System

15. Hair Transplantation (Treatment)

with gels or waxes, and eyelashes must be curled. Both must be trimmed and shaped. Use of donor trichophytic closure techniques can decrease visibility of donor scars. [ ] For patients with extensive alopecia or those with thin black hair and pale white scalp skin, major grafts still produce a tufted or artificial appearance. In response to these patients, in 1986, Dr Wayne Bradshaw introduced micrografting techniques that involved the use of single hairs as an alternative method of hair replacement (...) > Hair Transplantation Treatment & Management Updated: Dec 13, 2017 Author: Jeffrey S Epstein, MD, FACS; Chief Editor: Arlen D Meyers, MD, MBA Share Email Print Feedback Close Sections Sections Hair Transplantation Treatment Approach Considerations Nearly all men and most women who have androgenic or inherited pattern baldness can be treated with hair transplantation. As in all other elective cosmetic surgeries, the most important patient selection criterion in hair transplantation

2014 eMedicine.com

16. Hair Transplantation (Follow-up)

with gels or waxes, and eyelashes must be curled. Both must be trimmed and shaped. Use of donor trichophytic closure techniques can decrease visibility of donor scars. [ ] For patients with extensive alopecia or those with thin black hair and pale white scalp skin, major grafts still produce a tufted or artificial appearance. In response to these patients, in 1986, Dr Wayne Bradshaw introduced micrografting techniques that involved the use of single hairs as an alternative method of hair replacement (...) > Hair Transplantation Treatment & Management Updated: Dec 13, 2017 Author: Jeffrey S Epstein, MD, FACS; Chief Editor: Arlen D Meyers, MD, MBA Share Email Print Feedback Close Sections Sections Hair Transplantation Treatment Approach Considerations Nearly all men and most women who have androgenic or inherited pattern baldness can be treated with hair transplantation. As in all other elective cosmetic surgeries, the most important patient selection criterion in hair transplantation

2014 eMedicine.com

17. The spectrum of skin diseases in a black population in Durban, KwaZulu-Natal, South Africa. (PubMed)

and profiled the patients.Clinical charts of all black African patients seen between January 2003 and December 2010 in a private practice in Durban were reviewed. The diseases seen were described and the prevalence calculated.A total of 6664 patient charts were reviewed. The five most common conditions were acne, eczemas, dyschromias, infections, and hair disorders. These data agree with reports from other parts of the world.Selection bias was presented by a single private practice, thus data may (...) The spectrum of skin diseases in a black population in Durban, KwaZulu-Natal, South Africa. Precise knowledge of the prevalence and spectrum of skin diseases in a population allows for effective planning for provision of dermatology services and distribution of resources. There are no published data on the epidemiology of skin disorders in Durban, KwaZulu-Natal.We investigated the prevalence of skin diseases in black African patients attending a predominantly black private healthcare facility

2014 International Journal of Dermatology

18. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2017.77.6385 Journal of Clinical (...) Oncology - published online before print February 14, 2018 PMID: Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline x Julie R. Brahmer , x Christina Lacchetti , x Bryan J. Schneider , x Michael B. Atkins , x Kelly J. Brassil , x Jeffrey M. Caterino , x Ian Chau , x Marc S. Ernstoff , x Jennifer M. Gardner , x Pamela Ginex , x Sigrun Hallmeyer , x Jennifer Holter Chakrabarty , x

2018 American Society of Clinical Oncology Guidelines

19. Using Clinical Laboratory Tests to Monitor Drug Therapy in Pain Management Patients

to correctly detect outcomes. Strength of recommendation: A; Quality of evidence: III (pain management population), II (substance abuse disorder monitoring population) Studying patient non-compliance with the therapeutic regimen is difficult unless non-prescribed medications or illicit drugs are present in the tested matrix. Generally, testing frequency is low and the windows of detection in the different matrices (urine, oral fluid, blood/plasma/serum) are usually only a few days. Thus, most of the time (...) between biological testing, the patient is inadequately monitored. Even when the matrix has a longer win- dow of detection, such as for hair, minimum exposure is required to give a positive result, and differences in disposition can occur based on hair color for basic drugs, or for meconium, minimum exposure frequency is needed to produce positive test results. Therefore, additional means of monitoring are highly useful to improve the detection of non-compliance, such as pill counts and interviews

2018 American Academy of Pain Medicine

20. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations

) in patients with chronic pain who are prescribed opioids. Methods An interdisciplinary group of clinicians with expertise in pain, substance use disorders, and primary care conducted virtual meetings to review relevant literature and existing guidelines and share their clinical experience in UDM before reaching consensus recommendations. Results Definitive (e.g., chromatography-based) testing is recommended as most clinically appropriate for UDM because of its accuracy; however, institutional or payer (...) policies may require initial use of presumptive testing (i.e., immunoassay). The rational choice of substances to analyze for UDM involves considerations that are specific to each patient and related to illicit drug availability. Appropriate opioid risk stratification is based on patient history (especially psychiatric conditions or history of opioid or substance use disorder), prescription drug monitoring program data, results from validated risk assessment tools, and previous UDM. Urine drug

Full Text available with Trip Pro

2018 American Academy of Pain Medicine

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>